熱門資訊> 正文

BridgeBio计划于2033年发行5.5亿美元可转换票据

2026-01-15 05:09

BridgeBio Pharma(BBIO) 0

BridgeBio Pharma (BBIO) on Wednesday said it plans to offer $550 million of convertible senior notes due 2033 in a private placement to qualified institutional buyers.
The company said it expects to grant initial purchasers an option to buy up to an additional $82.5 million of notes.
Net proceeds are intended to be used to repurchase, settle conversion obligations related to, or repay at maturity a portion of its 2.50% convertible senior notes due 2027, as well as for general corporate purposes.
BridgeBio also said it plans to use up to $82.5 million of cash on hand to repurchase shares from certain note purchasers in privately negotiated transactions concurrent with the pricing of the notes.

BBIO -4.00% after hours to $74.64.
Source: Press Release

More on BridgeBio Pharma

BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript
BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study - Slideshow
BridgeBio targets 30%+ market share for Attruby while advancing late-stage pipeline and reporting $120.7M Q3 revenue
BridgeBio succeeds in late-stage encaleret study

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。